A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 as monotherapy or in combination with a BTKi in patients with Chronic Lymphocytic Leukemia (CLL) or Richter Syndrome
Relapsed Non Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Richter Syndrome|MYC Amplification|MYC Overexpression|MYC Translocation
DRUG: VIP152|DRUG: BTKi
Safety and Tolerability, Number of participants with adverse events as a measure safety and tolerability of high risk CLL and RS in monotherapy, Up to 3 years
Overall Response Rate, Tumor response evaluation based on the response criteria as applicable for CLL and Richter Syndrome, Up to 3 years|Duration of Response, Time at Which Response Criteria are Met for Complete Response or Partial Response (Whichever Occurs First) Until the First Date of Recurrence, Progression or Death per applicable response criteria, Up to 3 years|Progression Free Survival, Number of Participants Without Disease Progression per iwCLL guidelines for CLL \& Lugano Classification for NHL, Up to 3 years|Assessment of pharmacokinetics (PK) of VIP152, Maximum observed drug concentration in measured administration (Cmax) of VIP152, Cycle 1 Day 1 through Cycle 2 Day 1|Time To Next Treatment, time from first dose to the initiation of next dose or death, Up to 3 years
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 as monotherapy or in combination with a BTKi in patients with Chronic Lymphocytic Leukemia (CLL) or Richter Syndrome